SLGL

Sol-GelC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$100.00

Analysis reference price unavailable

Analysis 2026-04-17 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$72.00

Analysis reference price unavailable

Analysis 2026-04-17 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$40.00

Analysis reference price unavailable

Analysis 2026-04-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment should stay cautious-to-neutral. Primary-source evidence now supports a cleaner balance-sheet picture after the March 2026 raise, but the setup is still mostly a monitoring story centered on one late-2026 clinical readout, with weak near-term fundamental visibility and a recent pipeline setback outside SGT-610 [#6K-2026-03-24] [#PR-2025-12-17].

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystPost-offering cash reset reduces near-term financing pressureHigh impact

The March 23, 2026 underwritten offering was priced at $72.00 per share for roughly $33.1 million gross proceeds, with proceeds earmarked for SGT-610 development, pre-commercialization, and working capital, which likely lowers immediate financing pressure but leaves dilution fresh in the setup [#6K-2026-03-24].

2026-11-15eventSGT-610 Phase 3 topline data remains the defining value inflectionHigh impact

Management said SGT-610 Phase 3 topline results are expected in the fourth quarter of 2026, after reporting >80% recruitment in April 2025 and later completing enrollment; success would matter disproportionately now that SGT-210 has been deprioritized for Darier disease [#PR-2025-04-17] [#PR-2025-12-17].

2027-03-31catalystHigh-frequency BCC and pre-commercialization optionality can add upside only if Gorlin data workHigh impact

The company continues preparatory work for a potential Phase 3 program in high-frequency BCC and used the March 2026 financing to support SGT-610 pre-commercialization activities, but this optionality depends on successful Gorlin Phase 3 execution and is too early to underwrite aggressively [#PR-2025-12-17] [#6K-2026-03-24].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology